Public Employees Retirement Association of Colorado Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Public Employees Retirement Association of Colorado decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,714 shares of the biopharmaceutical company's stock after selling 5,541 shares during the period. Public Employees Retirement Association of Colorado's holdings in Gilead Sciences were worth $15,492,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Susquehanna Fundamental Investments LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $27,436,000. Gilder Gagnon Howe & Co. LLC boosted its holdings in Gilead Sciences by 88.5% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 37,144 shares of the biopharmaceutical company's stock valued at $3,431,000 after acquiring an additional 17,437 shares in the last quarter. Coldstream Capital Management Inc. increased its position in Gilead Sciences by 6.5% during the 4th quarter. Coldstream Capital Management Inc. now owns 24,378 shares of the biopharmaceutical company's stock valued at $2,252,000 after purchasing an additional 1,496 shares during the period. Capital Analysts LLC raised its holdings in Gilead Sciences by 8.5% in the 4th quarter. Capital Analysts LLC now owns 5,444 shares of the biopharmaceutical company's stock worth $503,000 after purchasing an additional 426 shares in the last quarter. Finally, UP Strategic Wealth Investment Advisors LLC lifted its position in shares of Gilead Sciences by 5.2% in the 4th quarter. UP Strategic Wealth Investment Advisors LLC now owns 4,844 shares of the biopharmaceutical company's stock worth $447,000 after purchasing an additional 241 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company's stock, valued at $17,893,713.60. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 302,785 shares of company stock valued at $30,540,875 in the last 90 days. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research reports. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $109.43.

Gilead Sciences Trading Up 2.2 %

NASDAQ:GILD traded up $2.33 during mid-day trading on Wednesday, hitting $106.54. 9,624,028 shares of the stock traded hands, compared to its average volume of 7,522,666. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The stock has a market capitalization of $132.66 billion, a price-to-earnings ratio of 287.95, a PEG ratio of 0.71 and a beta of 0.32. The firm's 50 day moving average is $109.00 and its two-hundred day moving average is $98.58.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. The company's revenue for the quarter was down .3% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.